Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
ALPINE IMMUNE SCIENCES, INC. (NVLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Alpine Immune Sciences Reports Second Quarter 2023 Financial Results --The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023--"
05/11/2023 8-K Quarterly results
Docs: "Alpine Immune Sciences Reports First Quarter 2023 Financial Results"
04/28/2023 8-K Quarterly results
03/23/2023 8-K Quarterly results
Docs: "Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results"
01/26/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF ALPINE IMMUNE SCIENCES, INC. ARTICLE I - CORPORATE OFFICES"
11/14/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
09/21/2022 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
Docs: "ALPINE IMMUNE SCIENCES, INC. 13,606,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT",
"AUSTIN BEIJING BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE"
09/12/2022 8-K Other Events  Interactive Data
08/11/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
07/19/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline -"
12/16/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Recent private placement enables expansion and acceleration of development plans across the portfolio -"
09/15/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
Docs: "Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results"
07/02/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "ALPINE IMMUNE SCIENCES, INC. $75,000,000 OF SHARES OF",
"AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE"
06/10/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
12/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors"
11/12/2020 8-K Quarterly results
Docs: "Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
08/11/2020 8-K Quarterly results
07/24/2020 8-K Quarterly results
06/18/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101 - Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60 million in an upfront cash payment; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones - Alpine Immune Sciences to conduct a phase 2 study in systemic lupus erythematosus during the option period - Alpine will host a conference call today at 8:30 a.m. ET -"
06/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2018 Equity Incentive Plan, as amended"
05/14/2020 8-K Quarterly results
03/30/2020 8-K Quarterly results
Docs: "Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results"
01/27/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ALPINE IMMUNE SCIENCES, INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Unless otherwise defined herein, the terms defined in the Alpine Immune Sciences, Inc. 2018 Equity Incentive Plan will have the same defined meanings in this Restricted Stock Unit Agreement which includes the Notice of Restricted Stock Unit Grant , Terms and Conditions of Restricted Stock Unit Grant, and all appendices and exhibits attached thereto . I. NOTICE OF RESTRICTED STOCK UNIT GRANT Participant Name: Address: The undersigned Participant has been granted the right to receive an Award of Restricted Stock Units, subject to the terms and conditions of the Plan and this RSU Agreement, as follows: Grant Number: Date of Grant: Vesting Commencement Date: Number of Restricted Stock Units: Vesting Schedul..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy